Akeso’s AK112 Lung Cancer Trial Reaches Completion: What Investors Should Watch Next

Akeso, Inc. (HK:9926) announced an update on their ongoing clinical study.

The Phase Ib/II trial titled “A Phase Ib/II Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With Advanced NSCLC” tests Akeso’s AK112 in late-stage non-small cell lung cancer. It aims to measure how well the drug controls tumors and how safe it is in patients whose cancers express PD-L1, a key immune marker linked to response.

AK112 is a lab-made antibody drug that targets both PD-1 and VEGF pathways, which are important in cancer growth and immune escape. The goal is to boost the body’s immune attack on tumors while also cutting off blood supply that feeds the cancer.

The study uses a single treatment group, so all enrolled patients receive AK112 and there is no random assignment to different arms. It is an open-label design, meaning doctors and patients know they are getting AK112, and the main purpose is to test treatment benefit rather than compare against a control.

The trial was first submitted in April 2021, marking the start of formal clinical tracking for investors. The most recent update was filed on February 27, 2026, signaling that the study is listed as completed and key data analysis is likely in progress or close to readout.

For Akeso (HK:9926), positive results could strengthen its position in lung cancer and support future pricing power and partnerships, especially in China’s crowded immuno-oncology market. Investors will compare AK112’s profile to established drugs from Merck, Bristol Myers Squibb, and domestic rivals to judge whether the asset can gain share or support licensing deals.

The updated listing confirms this AK112 study has reached completion and remains current on the ClinicalTrials portal, with more detailed results expected to be posted or reported there as they become available.

To learn more about HK:9926’s potential, visit the Akeso, Inc. drug pipeline page.